Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that preclinical data for the Company’s lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.

The ASGCT Poster Session will be on Thursday May 20 from 6:15 p.m. to 8:15 p.m. Eastern time, and poster presenters will be available during that time. The following poster highlighting Senesco’s preclinical data for SNS-01 will be presented:
  • Development and Preclinical Testing of Large Batches of SNS01 – an EIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of Multiple Myeloma Presented by Catherine Taylor, Department of Biology, University of Waterloo, Waterloo, Ontario, Canada, and Richard Dondero, Vice President of Research and Development, Senesco Technologies, Inc., New Brunswick, New Jersey, in Exhibit Hall C & B South, Poster Number #218.

“This study demonstrates that we have resolved earlier scale-up constraints and now have the ability to produce larger volumes of therapeutic. This accomplishment is of particular importance as it gives us confidence that we can produce and preserve ample quantity of drug for our planned Phase I human clinical trial in multiple myeloma,” commented Mr. Dondero.

The American Society of Gene Therapy (ASGT) is a non-profit medical and professional organization that represents researchers and scientists devoted to the discovery of new gene and cell therapies. ASGT was established in 1996 and with more than 2,000 members in the United States and worldwide, it is the largest association of individuals involved in gene and cell therapeutics.

About Senesco Technologies, Inc.

Senesco Technologies is leveraging proprietary technology that regulates cell death, or apoptosis. Accelerating apoptosis may have application in treating cancer, while delaying apoptosis may have application in certain inflammatory and ischemic diseases. The Company is preparing to initiative a human clinical trial in multiple myeloma with its lead therapeutic SNS-01. Senesco also has partnered with leading-edge companies engaged in agricultural biotechnology, and earns research and development fees for applying its gene-regulating platform technology to enhance its partners’ products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company’s products; success of the Company’s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company’s ability to meet its funding milestones under its financing transaction, the Company’s ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Copyright Business Wire 2010